Drug intelligence / Profile preview

levo-alpha-acetyl-methodol + buprenorphine + methadone

Development stage: Unknown
Lead developer: Hikma Pharmaceuticals
Modality: Small Molecules
Administration: Oral, Sublingual, Subcutaneous, Intravenous, Intramuscular, Transdermal, Rectal

Overview

This is a combination of three opioid pharmacotherapies used in the treatment of opioid dependence. LAAM (levo-alpha-acetyl-methodol), buprenorphine, and methadone are medications that have been studied together in clinical trials to compare their efficacy and safety profiles. LAAM and methadone are full opioid agonists, while buprenorphine is a partial agonist at the mu opioid receptor and an antagonist at the kappa receptor. These medications help reduce withdrawal symptoms and cravings in individuals with opioid use disorders.

Targets

MOR (Mu opioid receptor)KOR (Kappa opioid receptor)

Beyond the preview

Go deeper on levo-alpha-acetyl-methodol + buprenorphine + methadone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on levo-alpha-acetyl-methodol + buprenorphine + methadone.

Explore the full profile